^
    Back
    Association details:
    Biomarker:ERCC1 underexpression
    Cancer:Bladder Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    gemcitabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AUA 2022
    Title:

    MP56-07 PREDICTORS OF RESPONSE FOLLOWING NEOADJUVANT CISPLATIN BASED CHEMOTHERAPY FOR MUSCLE INVASIVE UROTHELIAL BLADDER CANCER USING MOLECULAR PROFILE

    Published date:
    04/09/2022
    Excerpt:
    Bivariate analysis showed that higher mRNA expression level of CTR, lower radiological stage preoperatively and lower mRNA gene expression levels of BRACA1 and ERCC1 were associated with good response to NAC preoperatively....Lower levels of gene expression of BRACA1, ERCC1& higher expression of CTR were the only factors which remained statistically significant in multivariate analysis by logistic regression (Table 1).
    DOI:
    10.1097/JU.0000000000002639.07